Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
01 May 2019
Historique:
pubmed: 11 1 2019
medline: 10 7 2019
entrez: 11 1 2019
Statut: ppublish

Résumé

Objective To assess the rate of successfully achieving treatment goals among Japanese men with hyperuricemia/gout and identify factors influencing the success rate. Methods This cross-sectional study, conducted from January to December 2012, examined the serum uric acid (SUA) levels and clinical characteristics of 2,103 men with hyperuricemia/gout selected from an initial population of 136,770 individuals who participated in a workplace health checkup. The success rates (defined as SUA ≤6.0 mg/dL) were calculated, and a multivariate analysis was used to identify factors associated with "therapeutic failure" to achieve target SUA levels. Results The rate of successfully achieving the target SUA level was 37.5%. The body mass index (BMI) was significantly associated with therapeutic failure [25.0≤ Category (C) 2<27.5, adjusted odds ratio (AOR) =1.35; 27.5≤C3<30.0, AOR=1.69; C4 ≥ 30.0, AOR=1.94; relative to C1<25.0]. A significant positive association was also observed between waist circumference (WC) and therapeutic failure (85≤C2<90, OR=1.29; 90≤C3<95, OR=1.41; 95≤C4, OR=2.28; relative to C1<85.0 cm). Those with higher BMI/WC measurements were significantly more likely to have higher SUA levels than those with lower such measurements. The ongoing intake of dyslipidemia medication was identified as a protective factor against therapeutic failure. Discussion Our findings suggest a possible association between obesity and therapeutic failure, underscoring the importance of maintaining lipid profiles as part of managing SUA levels. Better management of both obesity and dyslipidemia may prevent future cardiovascular disorders by ensuring healthier SUA levels.

Identifiants

pubmed: 30626825
doi: 10.2169/internalmedicine.1899-18
pmc: PMC6543211
doi:

Substances chimiques

Gout Suppressants 0
Uric Acid 268B43MJ25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1225-1231

Références

Metabolism. 2001 Jun;50(6):621-6
pubmed: 11398134
Hypertension. 2001 Nov;38(5):1101-6
pubmed: 11711505
Hypertens Res. 2002 Mar;25(2):185-90
pubmed: 12047033
J Am Soc Nephrol. 2002 Dec;13(12):2888-97
pubmed: 12444207
Arthritis Rheum. 2004 Jun 15;51(3):321-5
pubmed: 15188314
Am J Physiol Renal Physiol. 2006 Mar;290(3):F625-31
pubmed: 16234313
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Rheumatology (Oxford). 2010 Dec;49(12):2391-9
pubmed: 20805117
Nephrology (Carlton). 2011 Jul;16(5):518-21
pubmed: 21303423
Intern Med. 2011;50(11):1149-56
pubmed: 21628928
Nephrology (Carlton). 2011 Nov;16(8):767-76
pubmed: 21854506
Diabetol Metab Syndr. 2012 Feb 03;4(1):3
pubmed: 22301198
Am J Med. 2012 Sep;125(9):882-7.e1
pubmed: 22748400
Clin Chem. 1990 Jan;36(1):15-9
pubmed: 2297909
Hypertens Res. 2014 Mar;37(3):232-8
pubmed: 24173358
J Diabetes Investig. 2012 Feb 20;3(1):39-40
pubmed: 24843544
Mod Rheumatol. 2015 Sep;25(5):779-83
pubmed: 25671406
Arthritis Res Ther. 2015 Sep 22;17:263
pubmed: 26391224
BMC Cardiovasc Disord. 2015 Oct 16;15:129
pubmed: 26475463
JAMA. 2016 Jun 7;315(21):2345-7
pubmed: 27272587
Clin Rheumatol. 2017 Mar;36(3):649-656
pubmed: 27832384
J Rheumatol. 2017 Mar;44(3):388-396
pubmed: 28148699
Ann Rheum Dis. 2017 Nov;76(11):1870-1882
pubmed: 28866649
Int J Cardiol. 2018 Jun 15;261:183-188
pubmed: 29551256
Prev Med. 1972 Aug;1(3):409-21
pubmed: 5085007
JAMA. 1993 Jul 21;270(3):378-9
pubmed: 8315786

Auteurs

Akiko Katayama (A)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Hirohide Yokokawa (H)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Hiroshi Fukuda (H)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Yoshiki Ono (Y)

Department of Health Screening, Tokyo Health Service Association, Japan.

Hiroshi Isonuma (H)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Teruhiko Hisaoka (T)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Toshio Naito (T)

Department of General Medicine, Juntendo University School of Medicine, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH